Spotlight on Urology

Credits: 0.50 CME
Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum
Neal Shore, MD, FACS
University of Nebraska Medical Center

Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com

Urology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC

Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  • Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
  • Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
  • Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
  • Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Understanding the Disease Continuum and Navigating the Evolving Treatment Paradigms in Prostate Cancer

Understanding the Disease Continuum and Navigating the Evolving Treatment Paradigms in Prostate Cancer

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
  • Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
  • Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

William Oh, MD
Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/ Disclosure Statement

William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
  • Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
  • Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

William Oh, MD
Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/ Disclosure Statement

William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.50 CME
University of Nebraska Medical Center
Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum

Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com